Blood IFN-α2 levels decreased in both groups of COVID-19 patients over time (Figures 3A, S6) and did so regardless of the treatment group (usual care (UC), sarilumab, tocilizumab, or anakinra) (Figure 3B). Here, IFNA2 is linked to COVID-19.